Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

119.27
Delayed Data
As of 4:00pm ET
 -0.17 / -0.14%
Today’s Change
94.39
Today|||52-Week Range
127.00
+3.04%
Year-to-Date
Go With Allergan, Celgene and 'Big Mo'
10:04am / TheStreet.com - Paid Partner Content
Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb 20 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
7:54am / Zacks.com - Paid Partner Content
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
Feb 19 / MotleyFool.com - Paid Partner Content
3 Great Stocks to Buy Instead of NVIDIA Corporation
Feb 21 / MotleyFool.com - Paid Partner Content
Green Square Capital Llc Buys Landmark Infrastructure Partners LP, iShares Short-Term...
Feb 17 / GuruFocus News - Paid Partner Content
US exporters line up behind tax code overhaul
Feb 21 / FT.com - Paid Partner Content
Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
Feb 17 / Zacks.com - Paid Partner Content
3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter
Feb 20 / MotleyFool.com - Paid Partner Content
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
Feb 17 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close119.44
Today’s open121.39
Day’s range118.84 - 120.50
Volume3,831,785
Average volume (3 months)4,676,380
Market cap$92.9B
Dividend yield--
Data as of 4:00pm ET, 02/22/2017

Growth & Valuation

Earnings growth (last year)+28.35%
Earnings growth (this year)+21.56%
Earnings growth (next 5 years)+22.37%
Revenue growth (last year)+22.70%
P/E ratio47.9
Price/Sales8.51
Price/Book14.09

Competitors

 Today’s
change
Today’s
% change
AGNAllergan-0.84-0.34%
BMYBristol-Myers Squibb+0.57+1.04%
LLYEli Lilly and Co+0.71+0.88%
ABBVAbbVie-0.47-0.76%
Data as of 4:02pm ET, 02/22/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$1.63
Annual revenue (last year)$10.9B
Annual profit (last year)$2.0B
Net profit margin18.30%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President, Chief Operating Officer &
Director
Jacqualyn A. Fouse
Corporate headquarters
Summit, New Jersey

Forecasts


Search for Jobs